Atea Pharmaceuticals Inc expected to post a loss of 61 cents a share - Earnings Preview

Atea Pharmaceuticals

03/05/2024 12:47

* Atea Pharmaceuticals Inc  AVIR.OQ   AVIR.O  is expected
to show
no change in quarterly revenue when it reports  results on May 6
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Atea Pharmaceuticals Inc
is
for a loss of 61 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $3.50​, below​ its last closing price
of $3.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.49       -0.50      -0.47     Beat    5.4
 Sep. 30 2023  -0.45       -0.48      -0.40     Beat    16.1
 Jun. 30 2023  -0.45       -0.47      -0.34     Beat    27.7​
 Mar. 31 2023  -0.47       -0.48      -0.43     Beat    9.9
 ​​Dec.        -0.44       -0.45      -0.41     Beat    8.9
 31 2022                                                
 Sep. 30 2022  -0.41       -0.44      -0.10     Beat    77.4​
 Jun. 30 2022  -0.53       -0.52      -0.38     Beat    27.4
 Mar. 31 2022  -0.56       -0.58      -0.51     Beat    12.4
 This summary was machine generated May 3 at 11:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)